Top 20 breaking World Pharma News of 2018
- Details
- Category: Business
World Pharma News proudly presents the top 20 most popular breaking news from 2018. Have a wonderful 2019 New(s) Year filled with health, happiness, and spectacular success!
Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer
- Details
- Category: AstraZeneca
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, controlled, Phase III SOLO-3 trial of Lynparza (olaparib) tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment.
Merck assigns Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced it has evolved its agreement with Intrexon Corporation (NASDAQ: XON) for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells.
Amgen Golden Tickets provide startup companies with free lab space to further advance innovative science and technology
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018.
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors.
Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV™ (bevacizumab)
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin (bevacizumab).
Novartis receives European Commission approval for self-administration of Xolair® across all indications
- Details
- Category: Novartis
Novartis today announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment. With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
More Pharma News ...
- Amgen contributes $2 million to groundbreaking program providing cancer patients of all backgrounds access to U.S. clinical trials
- AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines
- FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
- GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
- Pfizer reaches a global agreement with AbbVie
- FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD
- Sanofi builds focus on rare blood disorders and cancers